english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

European Medicines Agency: insufficient transparency

In Focus The EMA's failings on transparency warrant an official inquiry, so that European decision-makers can take remedial action.
1 May 2022

Fostemsavir (Rukobia°) in multidrug-resistant HIV-1 infection

The initial treatment for patients with HIV-1 infection is based on a combination of antiretroviral drugs. Sometimes the virus is or becomes resistant to the various drug combinations that are available. How do Prescrire's editors rate fostemsavir (Rukobia°) in this situation?
1 May 2022

Pharmacobezoars may prolong effects of overdose

Pharmacobezoars are a possibility to be kept in mind when, after intentional overdose with drugs taken in a solid form, symptoms of overdose persist or reappear after initial improvement.
1 May 2022

Prescrire's Solidarity Support Programme: facilitating access to reliable and independent information around the world

1 May 2022

Cabotegravir (Vocabria°) and rilpivirine (Rekambys°) intramuscular injections in HIV infection

FEATURED REVIEW The standard treatment for patients with HIV infection is a combination of at least three antiretro­virals. An oral two-­drug regimen is sometimes considered. How do Prescrire's editors rate this combination, administered by intramuscular injection?
Full review (2 pages) available for download by subscribers.
1 April 2022

In the April issue of Prescrire International: Dupilumab (Dupixent°) in severe atopic eczema from 6 years of age

FREE DOWNLOAD Dupilumab is an immunosuppressant monoclonal antibody which was already authorised in the European Union for use in adults and adolescents with troublesome atopic eczema. How do Prescrire's editors rate this drug in younger children?
Full text available for free download.
1 April 2022

Balancing act

 Editorial  Making healthcare decisions is a balancing act, sometimes a tricky one. When the data are insubstantial or non-existent, the greater the uncertainty and the trickier the balancing act.
1 April 2022

The Innovative Medicines Initiative: a European public-private partnership that mostly benefits Big Pharma

IN FOCUSEurope's "Joint Technology Initiative on Innovative Medicines" (IMI) was created in 2007. The official objective was to improve the drug development process, so that the pharmaceutical sector could produce safer, more effective new drugs in the long term. How has the partnership measured up?
Full review (4 pages) available for download by subscribers.
1 April 2022

Drugs in 2021: a brief review

Just 17 of the 108 new marketing authorisations analysed and rated in our French edition in 2021 represented a major or notable therapeutic advance for patients. How does this finding for 2021 compare with prior years?
1 April 2022

Fentanyl: overdose and dependence with fast-acting forms

Fast-acting forms of fentanyl, a strong opioid analgesic, must be used with caution, patients must be thoroughly informed, and excessive doses must be avoided.
1 April 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90